SEC Comment Letter 0000000000-23-013885 to Entrada Therapeutics, Inc. (TRDA) (CIK 0001689375) (TRDA)
Entrada Therapeutics, Inc. (TRDA) (CIK 0001689375)
Date: Dec. 20, 2023 · CIK: 0001689375 · Accession: 0000000000-23-013885
AI Filing Summary & Sentiment
File numbers found in text: 001-40969
Letter
United States securities and exchange commission logo December 20, 2023 Kory Wentworth Chief Financial Officer Entrada Therapeutics, Inc. One Design Center Place Suite 17-500 Boston, MA 02210 Re:Entrada Therapeutics, Inc. Form 10-K for the Fiscal Year Ended December 31, 2022 Filed March 6, 2023 File No. 001-40969 Dear Kory Wentworth: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
December 20, 2023
Kory Wentworth
Chief Financial Officer
Entrada Therapeutics, Inc.
One Design Center Place
Suite 17-500
Boston, MA 02210
Re:Entrada Therapeutics, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2022
Filed March 6, 2023
File No. 001-40969
Dear Kory Wentworth:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences